(1S)-(6-Hydroxycarbamoyl-1-phenylcarbamoyl-hexyl)-carbamic Acid Benzyl Ester | 329967-33-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (1S)-(6-Hydroxycarbamoyl-1-phenylcarbamoyl-hexyl)-carbamic Acid Benzyl Ester
• 英文别名: benzyl N-[1-anilino-8-(hydroxyamino)-1,8-dioxooctan-2-yl]carbamate
• CAS: 329967-33-1
• 化学式: C₂₂H₂₇N₃O₅
• 分子量: 413.473
• InChiKey: ALFREMIRVGCWKP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  30
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  117
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  Py.BOP 、 (7S)-7-benzyloxycarbonylamino-7-phenylcarbamoyl-heptanoic acid 生成 (1S)-(6-Hydroxycarbamoyl-1-phenylcarbamoyl-hexyl)-carbamic Acid Benzyl Ester
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
  申请人：Sloan Kettering Institute for Cancer Research

  公开号：US20040002506A1

  公开（公告）日：2004-01-01

  The present invention provides the compound having the formula: 1 wherein each of R 1 and R 2 is, substituted or unsubstituted, aryl, cycloalkyl, cycloalkylamino, naphtha, pyridineamino, piperidino, t-butyl, aryloxy, arylalkyloxy, or pyridine group; wherein A is an amido moiety, —O—, —S—, —NH—, or —CH 2 —; and wherein n is an integer from 3 to 8. The present invention also provides a method of selectively inducing growth arrest, terminal differentiation and/or apoptosis of neoplastic cells and thereby inhibiting proliferation of such cells. Moreover, the present invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells. Lastly, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically acceptable amount of the compound above.

  本发明提供了具有以下式子的化合物：1其中R1和R2中的每一个都是取代或未取代的芳基，环烷基，环烷基氨基，萘基，吡啶氨基，哌啶基，叔丁基，芳基氧基，芳基烷氧基或吡啶基；其中A是酰胺基团，-O-，-S-，-NH-或-CH2-；n是从3到8的整数。本发明还提供了一种选择性诱导肿瘤细胞生长停滞、终端分化和/或凋亡的方法，从而抑制这些细胞的增殖。此外，本发明还提供了一种治疗具有肿瘤细胞增殖特征的患者的方法。最后，本发明提供了一种包含药学上可接受的载体和上述化合物的治疗上可接受的量的制药组合物。
• ANTI-CANCER PHOSPHONATE ANALOGS
  申请人：Boojamra Constantine G.

  公开号：US20100022467A1

  公开（公告）日：2010-01-28

  The invention is related to phosphorus substituted anti-cancer compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  本发明涉及磷取代的抗癌化合物、含有这些化合物的组合物以及包括给予这些化合物的治疗方法，还涉及用于制备这些化合物的过程和中间体。
• Treatment of neurodegenerative diseases and cancer of the brain with SAHA
  申请人：Sloan-Kettering Institute for Cancer Research

  公开号：EP2269609A2

  公开（公告）日：2011-01-05

  A composition comprising suberoylanilide hydroxamic acid (SAHA) represented by the following structure: or a pharmaceutically acceptable salt or hydrate thereof, and a Pharmaceutical acceptable carrier or diluent, for use in the treatment of brain cancer in a mammal, wherein the composition is formulated for oral administration.

  一种包含由以下结构表示的亚伯酰苯胺羟肟酸（SAHA）的组合物： 或其药学上可接受的盐或水合物，以及药学上可接受的载体或稀释剂，用于治疗哺乳动物的脑癌，其中该组合物配制成口服给药。
• Derivatives of 1-amino-1-(hetero)arylaminocarbonyl-6-hydroxyaminocarbonylhexane useful in the treatment of tumors
  申请人：Sloan-Kettering Institute for Cancer Research

  公开号：EP1231919B1

  公开（公告）日：2015-09-30
• TREATMENT OF NEURODEGENERATIVE DISEASES AND CANCER OF THE BRAIN
  申请人：Sloan-Kettering Institute For Cancer Research

  公开号：EP1443928B1

  公开（公告）日：2011-07-27